The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 07, 2023
Filed:
Jul. 09, 2019
Applicant:
University of Bern, Bern, CH;
Inventors:
Carsten Riether, Bern, CH;
Christian Schürch, Spiegel bei Bern, CH;
Adrian Ochsenbein, Hinterkappelen, CH;
Karen Silence, Overijse, BE;
Assignee:
University of Bern, Bern, CH;
Primary Examiner:
Int. Cl.
CPC ...
A61P 35/00 (2006.01); A61K 31/5025 (2006.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 31/506 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 31/506 (2013.01); A61K 31/5025 (2013.01); A61P 35/00 (2018.01); C07K 16/2875 (2013.01); C07K 16/2878 (2013.01); A61K 2039/505 (2013.01); C07K 2317/20 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract
Provided are methods and compositions for the treatment of a BCR-ABL1 related disorder (e.g., chronic myelogenous leukemia) using a therapeutic combination of a WNT signaling pathway inhibitor and a BCR-ABL1 tyrosine kinase inhibitor.